+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hyperoxaluria - Pipeline Insight, 2021

  • ID: 4037304
  • Drug Pipelines
  • March 2021
  • Region: Global
  • 120 pages
  • DelveInsight

FEATURED COMPANIES

  • Allen Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Biocodex
  • Chinook therapeutics
  • Federation Bio
  • OxThera
This “Hyperoxaluria - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Hyperoxaluria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
HYPEROXALURIA Understanding

HYPEROXALURIA: Overview

Hyperoxaluria is a condition that occurs when there is too much oxalate in the urine. Oxalate is a natural chemical in body and also contained in some foods, is normally eliminated from the body through the kidneys in the urine. Symptoms of hyperoxaluria can develop anytime from infancy to later adulthood (over 70 years of age). The most common initial symptom is usually kidney stones. Urine tests, Blood tests and scans may contribute to the diagnosis of Hyperoxaluria. The goal of treatment is to lower the level of oxalate in the body and prevent calcium oxalate crystals from forming in the kidneys and other body tissues.

"HYPEROXALURIA - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the HYPEROXALURIA pipeline landscape is provided which includes the disease overview and HYPEROXALURIA treatment guidelines. The assessment part of the report embraces, in depth HYPEROXALURIA commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, HYPEROXALURIA collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence HYPEROXALURIA R&D. The therapies under development are focused on novel approaches to treat/improve HYPEROXALURIA.

HYPEROXALURIA Emerging Drugs Chapters

This segment of the HYPEROXALURIA report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

HYPEROXALURIA Emerging Drugs

Oxabact: OxaThera

Oxalobacter formigenes is an anaerobe, non-pathogenic bacterium which exclusively uses oxalate as the energy source. OxThera has taken this bacterial strain isolated from the human gut and developed a live biotherapeutic product candidate. Oxabact is being studied in phase III stage of development for the treatment of primary hyperoxaluria.

Reloxiliase: Allen Pharmaceuticals

Reloxaliase (formerly ALLN-177), is a first-in-class, non-absorbed, orally-administered enzyme for the treatment of hyperoxaluria. Reloxaliase, a crystalline formulation of the enzyme oxalate decarboxylase, has been designed to specifically degrade oxalate within the GI tract, thus limiting systemic absorption of oxalate into the bloodstream. Reloxiliase is being evaluated for the treatment of Hyperoxaluria in phase III stage of development.

Stiripentol: Biocodex

Stiripentol is an orally active compound originated by Biocodex that inhibits several P450 cytochromes. Stiripentol developed by Biocodex is being studied in phase II stage of development for the treatment of primary Hyperoxluria.

HYPEROXALURIA: Therapeutic Assessment

This segment of the report provides insights about the different HYPEROXALURIA drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in HYPEROXALURIA

There are approx. 10+ key companies which are developing the therapies for HYPEROXALURIA. The companies which have their HYPEROXALURIA drug candidates in the most advanced stage, i.e. phase III include, OxaThera.

Phases

This report covers around 10+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
Route of Administration

HYPEROXALURIA pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Subcutaneous
  • Intravenous
  • Intramuscular
Molecule Type

Products have been categorized under various Molecule types such as
  • Bispecific Antibody
  • Peptides
  • Small molecule
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

HYPEROXALURIA: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses HYPEROXALURIA therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HYPEROXALURIA drugs.

HYPEROXALURIA Report Insights
  • HYPEROXALURIA Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
HYPEROXALURIA Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing HYPEROXALURIA drugs?
  • How many Hyperoxaluria drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of HYPEROXALURIA?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the HYPEROXALURIA therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for HYPEROXALURIA and their status?
  • What are the key designations that have been granted to the emerging drugs?

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Allen Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Biocodex
  • Chinook therapeutics
  • Federation Bio
  • OxThera
Introduction

Executive Summary

HYPEROXALURIA: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
HYPEROXALURIA - Analytical Perspective

In-depth Commercial Assessment
  • HYPEROXALURIA companies' collaborations, Licensing, Acquisition -Deal Value Trends
HYPEROXALURIA Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
Oxabact: OxaThera
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
Stiripentol: Biocodex
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I/II)
  • Comparative Analysis
SYNB8802: Synlogic
  • Product Description
  • Research and Development
  • Product Development Activities
Preclinical Stage Products
  • Comparative Analysis
CHK-339: Chinook therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
HYPEROXALURIA Key Companies

HYPEROXALURIA Key Products

HYPEROXALURIA- Unmet Needs

HYPEROXALURIA- Market Drivers and Barriers

HYPEROXALURIA- Future Perspectives and Conclusion

HYPEROXALURIA Analyst Views

HYPEROXALURIA Key Companies

Appendix

List of Tables
Table 1 Total Products for HYPEROXALURIA
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for HYPEROXALURIA
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
  • OxThera
  • Allen Pharmaceuticals
  • Biocodex
  • Alnylam Pharmaceuticals
  • Chinook therapeutics
  • Dicerna Pharmaceuticals, Inc.
  • Synlogic
  • Federation Bio
Note: Product cover images may vary from those shown
Adroll
adroll